NCT03831503 is a Phase 1 clinical trial of INO-A002 in Healthy Volunteers, sponsored by University of Pennsylvania.

Who is sponsoring NCT03831503?

NCT03831503 is sponsored by University of Pennsylvania.

What drugs are being tested in NCT03831503?

Interventions in NCT03831503: INO-A002, CELLECTRA® 2000, Dengue Fever Antibodies (IgG).

What condition does NCT03831503 study?

NCT03831503 studies Healthy Volunteers.

Is NCT03831503 still recruiting?

NCT03831503 is currently completed. Last updated 14 December 2023.

Last reviewed 2023-12-14 · How we verify

NCT03831503

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

Completed Phase 1 Last updated 14 December 2023

What this trial tests

Phase 1 trial testing INO-A002 in Healthy Volunteers in 30 participants. Completed in 3 October 2022.

Timeline

7 February 2019

Primary endpoint
3 October 2022

3 October 2022

Quick facts

Lead sponsor	University of Pennsylvania
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	30
Start date	7 February 2019
Primary completion	3 October 2022
Estimated completion	3 October 2022
Sites	1 location across United States

Drugs / interventions tested

INO-A002 — full drug profile →
CELLECTRA® 2000
Dengue Fever Antibodies (IgG)

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

University of Pennsylvania

Who can join

Adults 18 to 60, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1, open label, single center, dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of dMAb-ZK190 following delivery of INO-A002 with Hylenex® recombinant delivered IM followed by EP in healthy adult Dengue naïve volunteers ages 18-60 years.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

DNA vaccines: prime time is now.
Gary EN, Weiner DB. · · 2020 · cited 138× · PMID 32259744 · DOI 10.1016/j.coi.2020.01.006
In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies.
Patel A, Bah MA, Weiner DB. · · 2020 · cited 55× · PMID 32157600 · DOI 10.1007/s40259-020-00412-3
In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity.
Wise MC, Xu Z, Tello-Ruiz E, Beck C, et al · · 2020 · cited 37× · PMID 31697648 · DOI 10.1172/jci132779
Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases.
Xu Z, Patel A, Tursi NJ, Zhu X, et al · · 2020 · cited 32× · PMID 35047878 · DOI 10.3389/fmedt.2020.571030
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
Strohl WR, Ku Z, An Z, Carroll SF, et al · · 2022 · cited 31× · PMID 35476216 · DOI 10.1007/s40259-022-00529-7
Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing.
Whaley KJ, Zeitlin L. · · 2022 · cited 21× · PMID 34259613 · DOI 10.1080/21645515.2021.1930847
Novel Delivery Systems for Checkpoint Inhibitors.
Lamichhane P, Deshmukh R, Brown JA, Jakubski S, et al · · 2019 · cited 21× · PMID 31373327 · DOI 10.3390/medicines6030074
DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure.
Jacobs L, De Smidt E, Geukens N, Declerck P, et al · · 2020 · cited 17× · PMID 32101701 · DOI 10.1016/j.ymthe.2020.02.007

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03831503 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 14 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03831503.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing